Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD and cystic fibrosis. The Company is listed on the NASDAQ Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative theraputics.

Latest press releases

23 May 2018

Verona Pharma Files Shelf Registration Statement with SEC
LONDON, May 23, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA…

21 May 2018

Verona Pharma Presented Clinical Data at ATS 2018 that Further Highlights RPL554 as a First-in-Class Treatment for COPD
LONDON, May 21, 2018…

Video

Unique mechanism of action

Our breakthrough lead product, RPL554, is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases

Go

Current share price

155.00p

-2.50 (-1.59%)

LON: VRP
 

16.24USD

0.01 (0.06%)

NASDAQ: VRNA
 

Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

E: info@veronapharma.com
T: +44 (0)203 283 4200

 

 

Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
ICR, Inc.
E: ICR_Verona@icrinc.com
T: +1 646-277-1282

UK Investor relations contact
FTI Consulting
E: veronapharma@fticonsulting.com
T: +44 (0)20 3727 1000

Nominated adviser and broker
Stifel Nicolaus Europe Limited
150 Cheapside
London EC2V 6ET
United Kingdom

T: +44 (0)207 710 7600

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us